🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in Canada / NCT07417280
Recruiting Not applicable

LIFUS For Neurological Disorders

NCT07417280 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2025-12-02
Last updated
2026-08-13

Condition(s) studied

Parkinson's Disease (PD)Essential TremorOrthostatic TremorDystoniaEpilepsySubstance Abuse DisorderDeep Brain Stimulation

Investigational drug(s) / intervention(s)

LIFUSSham LIFUS

LIFUS: Low-intensity focused ultrasound neuromodulation delivered to targeted cortical and/or subcortical brain regions to transiently modulate neural activity. LIFUS may be applied alone or in combination with concurrent neurophysiological assessments (e.g., TMS-evoked motor evoked potentials, EEG recordings, or DBS local field potential sensing) depending on the study component.

Sham LIFUS: Sham low-intensity focused ultrasound stimulation designed to mimic the sensory and procedural aspects of active LIFUS without delivering therapeutic ultrasound energy. The sham condition serves as a control to maintain blinding of participants and investigators.

Study summary

Low intensity focused ultrasound (LIFUS) has the potential to be used as a means of non-invasive neuro-modulation. To this day, the use of LIFUS is under investigation. Studies in healthy subjects have shown that application of LIFUS to the motor region of the brain can mildly decrease neuron excitability in healthy controls. The purpose of the present study is to evaluate the effects of LIFUS on brain tissue excitability in patients with movement disorders in order to elucidate the therapeutic potential of LIFUS.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: * 18-85 years of age * Patients diagnosed with neurological disorders, (such as epilepsy, brain tumour, movement disorders) or psychiatric disorders (such as substance abuse disorder) * Patients undergoing medical or surgical treatment (such as DBS) for neurological disorders Exclusion Criteria: * History of stroke * Comorbid dementia * Scored below 22 on the Montreal Cognitive Assessment (MoCA) * Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD) * Presence of metal implanted in body that is contraindicated in TMS/MRI * Pregnancy * Major depression/psychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study * Receiving a psychotropic medication or taking recreational substances that in the opinion of the investigator will significantly affect safety of the protocol * Major systemic illness or infection

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Toronto Western Hospital, 399 Bathurst St Toronto Ontario Recruiting

More University Health Network, Toronto trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07417280 on ClinicalTrials.gov ↗ ← All trials in Canada